The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Philip C. Amrein
No relevant relationships to disclose
Eyal C. Attar
No relevant relationships to disclose
Amir Tahmasb Fathi
No relevant relationships to disclose
Steven L McAfee
No relevant relationships to disclose
Martha Wadleigh
No relevant relationships to disclose
Daniel J. DeAngelo
No relevant relationships to disclose
David P. Steensma
No relevant relationships to disclose
Julia Foster
No relevant relationships to disclose
Richard M. Stone
Consultant or Advisory Role - Celgene
Donna S. Neuberg
No relevant relationships to disclose
Karen K. Ballen
No relevant relationships to disclose